Is DYN stock safe? | Glauxie AI

Q: Is DYN stock safe?

Dyne Therapeutics, Inc. (DYN) operates in the Biotechnology industry (Healthcare sector). The company is led by CEO John G. Cox. Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops... Employees: 55,000.

Q: What are the risks of investing in DYN?

Identify key risks of investing in DYN — debt, competition, volatility, and sector headwinds.

Q: Is DYN a good long-term investment?

Evaluate DYN as a long-term investment using fundamental scores, growth metrics, and risk assessment.

Q: How much debt does DYN have?

Review DYN total debt, debt-to-equity ratio, interest coverage, and leverage trends.

Is DYN stock safe?

🦉

Dyne Therapeutics, Inc. (DYN)

Company Overview

Sector / IndustryHealthcare / Biotechnology

CEOJohn G. Cox

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral...

Key Executives

Name	Title
Axel Wiest	Senior VP and Head of Portfolio Strategy & Operations
Daniel Wilson	Senior Vice President & Head of Legal
Debra Feldman	Chief Regulatory Affairs Officer
Douglas Kerr	Chief Medical Officer
Erick J. Lucera	Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer and Treasurer
James Bilotta	Chief Digital & Information Officer

Financial Health

Risk Assessment

Weather Score0/100

RegimeN/A

DYN Profile Financials

What are the risks of investing in DYN? Is DYN a good long-term investment? How much debt does DYN have?